Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2020

Nov 12, 2020

SELL
$6.09 - $9.15 $154,119 - $231,559
-25,307 Closed
0 $0
Q2 2020

Aug 10, 2020

BUY
$7.98 - $10.44 $201,949 - $264,205
25,307 New
25,307 $235,000

Others Institutions Holding XFOR

About X4 Pharmaceuticals, Inc


  • Ticker XFOR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 68,646,096
  • Market Cap $55.6M
  • Description
  • X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase...
More about XFOR
Track This Portfolio

Track Martingale Asset Management L P Portfolio

Follow Martingale Asset Management L P and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Martingale Asset Management L P, based on Form 13F filings with the SEC.

News

Stay updated on Martingale Asset Management L P with notifications on news.